Securian Asset Management Inc. Lowers Stake in Johnson & Johnson (NYSE:JNJ)

Securian Asset Management Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,496 shares of the company's stock after selling 1,903 shares during the period. Johnson & Johnson accounts for 0.6% of Securian Asset Management Inc.'s portfolio, making the stock its 27th largest holding. Securian Asset Management Inc.'s holdings in Johnson & Johnson were worth $21,144,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MRP Capital Investments LLC grew its position in Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after acquiring an additional 65 shares in the last quarter. Syverson Strege & Co grew its position in Johnson & Johnson by 4.9% in the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after acquiring an additional 65 shares in the last quarter. MBA Advisors LLC grew its position in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after acquiring an additional 68 shares in the last quarter. Sovereign Financial Group Inc. grew its position in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after acquiring an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc grew its position in Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after acquiring an additional 69 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 0.5%

NYSE:JNJ traded up $0.78 during trading hours on Friday, reaching $163.76. The company's stock had a trading volume of 5,398,098 shares, compared to its average volume of 9,102,176. The stock has a 50 day moving average price of $154.10 and a two-hundred day moving average price of $154.84. The company has a market capitalization of $394.01 billion, a P/E ratio of 17.53, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.82 earnings per share. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.18%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday. Barclays boosted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday. Finally, Raymond James Financial dropped their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Eleven investment analysts have rated the stock with a hold rating, nine have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus target price of $174.11.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.